Corrigendum to ‘Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis’ International Journal of Infectious Diseases, Volume 119, June 2022, Page 130-139

Correction From: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. To: This work was supported by the National Research Foundation of Korea, [grant number NRF-2021R1I1A2059735]. The authors apologise for this error. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-AnalysisInternational Journal of Infectious DiseasesVol. 119PreviewMore than 233 million people have been infected with SARS-CoV-2, and 4.7 million people have died of the disease worldwide (as of 1 October 2021). Several vaccines have been developed concerning this public health problem, and 6.2 billion doses have already been administered (COVID-19 Map - Johns Hopkins Coronavirus Resource Center, October 1, 2021). A phase-III clinical trial of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine included 12,021 participants from the United Kingdom, Brazil, and South Africa, and reported no adverse events related to unusual thrombotic events (Voysey et al., 2021). Full-Text PDF Open Access